Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Given the complex set of opinions handed down by the U.S. Supreme Court in its 6-3 vote allowing work on Maine’s prescription drug program to continue, states have been forced to try to determine what impact the decision will have on their efforts to control pharmacy costs and to make cost-effective drugs available to those who need them.

In the wake of the Supreme Court decision on Maine’s drug program, states look for direction